Aurisco Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of June 2025: 4.08%

Aurisco Pharmaceutical Co Ltd (605116) has an Asset Resilience Ratio of 4.08% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Aurisco Pharmaceutical Co Ltd's working capital to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥159.28 Million

≈ $23.31 Million USD Cash + Short-term Investments

Total Assets

CN¥3.90 Billion

≈ $571.06 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2024–2024)

This chart shows how Aurisco Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 605116 total asset value.

Liquid Assets Composition Over Time

This chart breaks down Aurisco Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Aurisco Pharmaceutical Co Ltd (605116) financial obligations for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥159.28 Million	4.08%
Total Liquid Assets	CN¥159.28 Million	4.08%

Asset Resilience Insights

Limited Liquidity: Aurisco Pharmaceutical Co Ltd maintains only 4.08% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Aurisco Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Aurisco Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Abivax SA PA:ABVX	Biotechnology	2.58%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%
Pulike Biological Engineering SHG:603566	Biotechnology	17.82%
Rocket Pharmaceuticals Inc NASDAQ:RCKT	Biotechnology	14.00%
NEWRON PHARMACEUT. EO-20 XETRA:NP5	Biotechnology	41.67%
Upstream Bio, Inc. NASDAQ:UPB	Biotechnology	64.70%

Annual Asset Resilience Ratio for Aurisco Pharmaceutical Co Ltd (2024–2024)

The table below shows the annual Asset Resilience Ratio data for Aurisco Pharmaceutical Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	7.73%	CN¥299.83 Million ≈ $43.87 Million	CN¥3.88 Billion ≈ $567.39 Million	--

pp = percentage points

About Aurisco Pharmaceutical Co Ltd

SHG:605116 China Biotechnology

Market Cap

$1.19 Billion

CN¥8.16 Billion CNY

Market Cap Rank

#8215 Global

#1923 in China

Share Price

CN¥20.08

Change (1 day)

-0.50%

52-Week Range

CN¥18.37 - CN¥34.43

All Time High

CN¥34.43